# Hoffmann-La Roche: Phase 3 study in Early Breast Cancer, Estrogen Receptor-Positive Breast Cancer (1500 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study to Learn How Well Participants With a Specific Type of Early Breast Cancer (ER-Positive, HER2-Negative) Tolerate and Stay on Treatment With Giredestrant and How They Feel During Treatment |
| NCT ID | NCT07827573 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Early Breast Cancer; Estrogen Receptor-Positive Breast Cancer; HER2-Negative Breast Cancer |
| Intervention types | drug |
| Target enrollment | 1500 |
| Posted | 2026-09-18 |
| Planned start | 2026-10-30 |
| Event | Newly registered study |
| Event date | 2026-09-18 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 1500 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07827573). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.